Dementia medications and risk of falls, syncope, and related adverse events: Meta-analysis of randomized controlled trials

Journal of the American Geriatrics Society

Volumn 59, Issue 6, 2011, Pages 1019-1031

  Kim, Dae Hyun ^a,b,c   Brown, Rebecca T ^a   Ding, Eric L ^b   Kiel, Douglas P ^a   Berry, Sarah D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

cholinesterase inhibitors; dementia; falls; memantine; syncope

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; TACRINE;

ACCIDENTAL INJURY; ADVERSE OUTCOME; ARTICLE; COCHRANE LIBRARY; COGNITIVE DEFECT; COMMUNITY CARE; DEMENTIA; DRUG EFFECT; EMBASE; FALLING; FOLLOW UP; FRACTURE; HUMAN; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; NURSING HOME; SIDE EFFECT; SYNCOPE; SYSTEMATIC REVIEW;

ACCIDENTAL FALLS; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DOPAMINE AGENTS; FEMALE; FRACTURES, BONE; HUMANS; MALE; MEMANTINE; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK FACTORS; SYNCOPE; WOUNDS AND INJURIES;

EID: 79958786388     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03450.x     Document Type: Article

References (94)

1. van Dijk PT, Meulenberg OG, van de Sande HJ, et al,. Falls in dementia patients. Gerontologist 1993; 33: 200-204. (Pubitemid 23110606)
2. Morris JC, Rubin EH, Morris EJ, et al,. Senile dementia of the Alzheimer's type: An important risk factor for serious falls. J Gerontol 1987; 42: 412-417. (Pubitemid 17103783)
3. Tinetti ME, Speechley M, Ginter SF., Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319: 1701-1707. (Pubitemid 19019577)
4. Stevens JA, Corso PS, Finkelstein EA, et al,. The costs of fatal and non-fatal falls among older adults. Inj Prev 2006; 12: 290-295. (Pubitemid 44621760)
5. Tinetti ME, Williams CS., Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997; 337: 1279-1284. (Pubitemid 27461284)
6. Tanaka A, Okuzumi H, Kobayashi I, et al,. Gait disturbance of patients with vascular and Alzheimer-type dementias. Percept Mot Skills 1995; 80: 735-738.
7. Sheridan PL, Hausdorff JM., The role of higher-level cognitive function in gait: Executive dysfunction contributes to fall risk in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24: 125-137. (Pubitemid 47094072)
8. Sterke CS, Verhagen AP, van Beeck EF, et al,. The influence of drug use on fall incidents among nursing home residents: A systematic review. Int Psychogeriatr 2008; 20: 890-910.
9. van Doorn C, Gruber-Baldini AL, Zimmerman S, et al,. Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc 2003; 51: 1213-1218. (Pubitemid 37093569)
10. Passant U, Warkentin S, Gustafson L., Orthostatic hypotension and low blood pressure in organic dementia: A study of prevalence and related clinical characteristics. Int J Geriatr Psychiatry 1997; 12: 395-403. (Pubitemid 27148464)
11. Gillespie LD, Gillespie WJ, Robertson MC, et al,. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003;:CD000340.
12. Shaw FE, Bond J, Richardson DA, et al,. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: Randomised controlled trial. BMJ 2003; 326: 73.
13. Coussement J, De PL, Schwendimann R, et al,. Interventions for preventing falls in acute- and chronic-care hospitals: A systematic review and meta-analysis. J Am Geriatr Soc 2008; 56: 29-36.
14. Morden NE, Zerzan JT, Larson EB., Alzheimer's disease medication: Use and cost projections for Medicare Part D. J Am Geriatr Soc 2007; 55: 622-624. (Pubitemid 46496577)
15. Birks J, Harvey RJ., Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD001190.
16. Birks J, Grimley EJ, Iakovidou V, et al,. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;(2):CD001191.
17. Craig D, Birks J., Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006;(1):CD004746.
18. Farlow MR, Graham SM, Alva G., Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials. Drug Saf 2008; 31: 577-585. (Pubitemid 351861950)
19. Montero-Odasso M, Wells J, Borrie M., Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc 2009; 57: 359-360.
20. Assal F, Allali G, Kressig RW, et al,. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc 2008; 56: 946-947. (Pubitemid 351652394)
21. Bordier P, Lanusse S, Garrigue S, et al,. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005; 22: 687-694. (Pubitemid 41138980)
22. Fisher AA, Davis MW., Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 2008; 42: 278-283. (Pubitemid 351238578)
23. Gallini A, Sommet A, Montastruc JL., Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf 2008; 17: 877-881.
24. Kayrak M, Yazici M, Ayhan SS, et al,. Complete atrioventricular block associated with rivastigmine therapy. Am J Health Syst Pharm 2008; 65: 1051-1053. (Pubitemid 351768739)
25. Gill SS, Anderson GM, Fischer HD, et al,. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009; 169: 867-873.
26. Derry S, Kong LY, Aronson JK., Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001; 1: 7.
27. Ioannidis JP, Evans SJ, Gotzsche PC, et al,. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 2004; 141: 781-788. (Pubitemid 39524916)
28. Howard RJ, Juszczak E, Ballard CG, et al,. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-1392. (Pubitemid 47535593)
29. van Dyck CH, Tariot PN, Meyers B, et al,. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 136-143. (Pubitemid 46878975)
30. Winblad B, Gauthier S, Scinto L, et al,. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024-2035.
31. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer's type [on-line]. Available at Accessed June 11, 2009.
32. A long-term extension study evaluating the safety and tolerability of BID and QD administration of memantine in patients with mild to moderate dementia of the Alzheimer's type [on-line]. Available at Accessed July 21, 2009.
33. A 52-week, open-label treatment extension to a 24-week prospective, randomized, multicenter, double-blind, placebo-controlled, parallel-group comparison of the efficacy, tolerability, and safety of rivastigmine capsules 3-12 mg/day in patients with probable vascular dementia [on-line]. Available at Accessed July 11, 2009.
34. Auchus AP, Brashear HR, Salloway S, et al,. Galantamine treatment of vascular dementia: A randomized trial. Neurology 2007; 69: 448-458. (Pubitemid 47450280)
35. Ballard C, Sauter M, Scheltens P, et al,. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: The VantagE study. Curr Med Res Opin 2008; 24: 2561-2574.
36. Barone P, Burn DJ, van LT, et al,. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008; 23: 1532-1540.
37. Black S, Roman GC, Geldmacher DS, et al,. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330. (Pubitemid 37221934)
38. Brodaty H, Corey-Bloom J, Potocnik FC, et al,. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 120-132. (Pubitemid 41191627)
39. Bullock R, Erkinjuntti T, Lilienfeld S., Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17: 29-34. (Pubitemid 37499964)
40. Darreh ST, Kadir A, Almkvist O, et al,. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 2008; 29: 168-184.
41. Emre M, Aarsland D, Albanese A, et al,. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518. (Pubitemid 39603164)
42. Erkinjuntti T, Kurz A, Gauthier S, et al,. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 2002; 359: 1283-1290. (Pubitemid 34310633)
43. Lyketsos CG, Reichman WE, Kershaw P, et al,. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 473-482. (Pubitemid 39181062)
44. Mohs RC, Doody RS, Morris JC, et al,. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-488. (Pubitemid 32757597)
45. Ott BR, Blake LM, Kagan E, et al,. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol 2007; 254: 351-358. (Pubitemid 46399200)
46. Peskind ER, Potkin SG, Pomara N, et al,. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704-715. (Pubitemid 44196270)
47. Poewe W, Wolters E, Emre M, et al,. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. Mov Disord 2006; 21: 456-461.
48. Raskind MA, Peskind ER, Wessel T, et al,. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268. (Pubitemid 30416276)
49. Rockwood K, Dai D, Mitnitski A., Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry 2008; 23: 207-214. (Pubitemid 351308502)
50. Rogers SL, Farlow MR, Doody RS, et al,. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
51. Rogers SL, Doody RS, Mohs RC, et al,. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031. (Pubitemid 28213580)
52. Small G, Erkinjuntti T, Kurz A, et al,. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs 2003; 17: 905-914. (Pubitemid 37211113)
53. Tariot PN, Solomon PR, Morris JC, et al,. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
54. U.S. Food and Drug Administration. NDA 020070 [on-line]. Available at Accessed July 21, 2009.
55. U.S. Food and Drug Administration. NDA 21-169 [on-line]. Available at Accessed July 21, 2009.
56. U.S. Food and Drug Administration. NDA 021615 [on-line]. Available at Accessed July 21, 2009.
57. Wilkinson D, Murray J., Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 852-857. (Pubitemid 32926767)
58. Wilkinson D, Doody R, Helme R, et al,. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 2003; 61: 479-486. (Pubitemid 37025364)
59. Winblad B, Engedal K, Soininen H, et al,. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495. (Pubitemid 32757598)
60. Loke Y, Price D, Herxheimer A., Including adverse effects in your review. Cochrane Adverse Effects Subgroup [on-line]. Available at Accessed August 4, 2009.
61. DerSimonian R, Laird N., Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
62. Higgins JP, Thompson SG., Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
63. Begg CB, Mazumdar M., Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
64. Egger M, Davey SG, Schneider M, et al,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
65. A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety, and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease [on-line]. Available at Accessed July 21, 2009.
66. Doody RS, Ferris SH, Salloway S, et al,. Donepezil treatment of patients with MCI. A 48-week randomized, placebo-controlled trial. Neurology 2009; 72: 1555-1561.
67. Feldman H, Gauthier S, Hecker J, et al,. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620. (Pubitemid 32782987)
68. Homma A, Takeda M, Imai Y, et al,. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299-313.
69. Homma A, Imai Y, Tago H, et al,. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008; 25: 399-407. (Pubitemid 351630073)
70. Rogers SL, Friedhoff LT., The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303. (Pubitemid 26341258)
71. Seltzer B, Zolnouni P, Nunez M, et al,. Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852-1856. (Pubitemid 39612945)
72. Tariot PN, Cummings JL, Katz IR, et al,. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-1599. (Pubitemid 34007984)
73. Winblad B, Kilander L, Eriksson S, et al,. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-1065.
74. Burns A, Bernabei R, Bullock R, et al,. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009; 8: 39-47.
75. Wilcock GK, Lilienfeld S, Gaens E., Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449.
76. Winblad B, Cummings J, Andreasen N, et al,. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-467. (Pubitemid 46831690)
77. Wilcock G, Mobius HJ, Stoffler A., A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305. (Pubitemid 35283717)
78. Tariot PN, Farlow MR, Grossberg GT, et al,. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004; 291: 317-324. (Pubitemid 38101604)
79. Reisberg B, Doody R, Stoffler A, et al,. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63: 49-54. (Pubitemid 43063861)
80. Porsteinsson AP, Grossberg GT, Mintzer J, et al,. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83-89. (Pubitemid 351536358)
81. Bakchine S, Loft H., Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13: 97-107. (Pubitemid 351365621)
82. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer's type, with a long-term, open-label extension study [on-line]. Available at Accessed June 6, 2009.
83. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with moderate-to-severe dementia of the Alzheimer's type [on-line]. Available at Accessed June 6, 2009.
84. A long-term extension study evaluating the safety and tolerability of four memantine dosing regimens in patients with moderate to severe dementia of the Alzheimer's type [on-line]. Available at Accessed June 6, 2009.
85. A randomized, double-blind, placebo-controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer's disease [on-line]. Available at Accessed June 6, 2009.
86. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in noninstitutionalized agitated patients with moderate to severe Alzheimer's disease [on-line]. Available at Accessed June 6, 2009.
87. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with moderate-to-severe dementia of the Alzheimer's type [on-line]. Available at Accessed June 6, 2009.
88. An open-label extension study evaluating the safety and tolerability of memantine in patients with moderate to severe dementia of the Alzheimer's type [on-line]. Available at Accessed July 21, 2009.
89. Masuda Y., Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease-from basic research to bedside. Curr Alzheimer Res 2004; 1: 315-321.
90. Kenny RA, Kalaria R, Ballard C., Neurocardiovascular instability in cognitive impairment and dementia. Ann N Y Acad Sci 2002; 977: 183-195. (Pubitemid 35418154)
91. Hinoi E, Fujimori S, Yoneda Y., Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts. FASEB J 2003; 17: 1532-1534.
92. Merle B, Itzstein C, Delmas PD, et al,. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J Cell Biochem 2003; 90: 424-436. (Pubitemid 37222209)
93. Huang CF, Su MJ., Positive inotropic action of NMDA receptor antagonist (+)-MK801 in rat heart. J Biomed Sci 1999; 6: 387-398.
94. Leung JC, Travis BR, Verlander JW, et al,. Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am J Physiol Regul Integr Comp Physiol 2002; 283: R964-R971.